Floatz logo

Arimidex

Progesterone Receptor-positive Breast Cancer

Ruth O'ReganPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Progesterone Receptor-positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Jennifer Lee Caswell-Jin
Phase 2BB
Letrozole
Ruth O'Regan
Phase 2BB
Cyclophosphamide
University of Washington
Phase 2B
FILGRASTIM
University of Washington
Phase 2B
Thiotepa
Fred Hutchinson Cancer Center
Phase 2B

View all 37 →

Same molecule, other indications

Arimidex is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
74 / 100
View asset →
hypogonadotropic hypogonadismDormant
BBB
Indicative ·
73 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →